---
title: A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)
nct_id: NCT05420909
overall_status: COMPLETED
sponsor: Bristol-Myers Squibb
study_type: OBSERVATIONAL
primary_condition: Metastatic Colorectal Cancer (mCRC)
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05420909.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05420909"
ct_last_update_post_date: 2022-08-19
last_seen_at: "2026-05-12T06:36:24.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)

**Official Title:** Overall Survival for Metastatic Colorectal Cancer Patients Matched to CHECKMATE-142

**NCT ID:** [NCT05420909](https://clinicaltrials.gov/study/NCT05420909)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 124
- **Lead Sponsor:** Bristol-Myers Squibb
- **Conditions:** Metastatic Colorectal Cancer (mCRC)
- **Start Date:** 2019-01-28
- **Completion Date:** 2019-04-01
- **CT.gov Last Update:** 2022-08-19

## Brief Summary

The purpose of this study is to estimate the overall survival (OS) for US participants diagnosed with metastatic colorectal cancer (mCRC) by using Flatiron Health's individual patient level data.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Metastatic Colorectal Cancer (CRC) participants in the Flatiron database as defined by:
* Diagnosed with CRC (ICD-9 153.x or 154.x or ICD-10 C18x, or C19x, or C20x, or C21x)
* Pathology consistent with CRC
* At least two documented clinical visits on or after January 1, 2013
* Evidence of Stage IV or recurrent metastatic CRC diagnosed on or after January 1, 2013
* Participants with high levels of microsatellite instability (MSI-H) and/or mismatch repair (MMR) protein deficiency (dMMR)
* Participants who received 2L therapy of interest on or after the initial mCRC diagnosis date
* Participants who had at least 1 month medical data during the prior to and post periods; however, participants who died within 1 month after the index date will not be excluded from the study

Exclusion Criteria:

* Participants \<18 years of age at index date
* Participants who received clinical trial drug during the prior or post periods
```

## Arms

- **Cohort 1** — Participants diagnosed with metastatic colorectal cancer (mCRC) selected from the Flatiron Electronic Health Record database

## Primary Outcomes

- **Overall Survival (OS)** _(time frame: Up to 6 years)_
- **Duration of Systemic Treatment** _(time frame: Up to 6 years)_ — Durations were reported for the first line of therapy prior to the second line (2L) therapy of interest, the 2L therapy of interest, the third line of therapy, and the at least fourth line of therapy.

## Locations (1)

- Local Institution, Princeton, New Jersey, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.local institution|princeton|new jersey|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05420909.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05420909*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*